NuScale Power Stock Slides 77% as Market Reassesses Small Reactor Prospects

The Motley FoolThe Motley Fool
|||2 min read
Key Takeaway

NuScale Power stock plummeted 77% amid market concerns about small reactor viability, despite securing regulatory approval for a Romania project expected online in 2033.

NuScale Power Stock Slides 77% as Market Reassesses Small Reactor Prospects

NuScale Power's share price has experienced a significant contraction in 2025, declining from its October peak of $57.42 to approximately $13—a 77% drop that reflects broader market concerns about the small modular reactor (SMR) sector's near-term viability. The decline stems from multiple headwinds, including third-quarter earnings misses, shareholder dilution, and the departure of major investor Fluor Corporation, which had previously supported the company's development efforts. These factors have prompted investors to recalibrate expectations regarding the commercial timeline and return potential of advanced nuclear technologies.

Despite the valuation compression, NuScale achieved a notable milestone with regulatory approval for its first commercial project in Romania through a partnership with Nuclearelectrica. This international approval represents tangible progress in validating the company's small modular reactor technology and demonstrates market interest beyond its home market. However, the project's expected commercial operation date of 2033 underscores the extended capital and development cycles inherent in the nuclear sector.

Analysts view the current stock level as presenting a high-risk, high-reward proposition. The company's ability to transition from approved projects to sustained commercial revenue generation remains dependent on regulatory advancement, project financing, and broader energy market conditions. Investors considering exposure should assess their risk tolerance carefully, as the path to profitability involves substantial execution risks and extended timelines.

Source: The Motley Fool

Back to newsPublished Feb 24

Related Coverage

GlobeNewswire Inc.

Forge Nano Expands to Taiwan, Targets AI Photonics Market With Proven ALDx Technology

Forge Nano opens Taiwan engineering office to serve AI data center photonics market, backed by ALDx technology achieving 23% insertion loss reduction and manufacturing partnerships.

TSMUMC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
The Motley Fool

SMR Potential vs. Proven Profits: NuScale and Constellation Battle for Nuclear Leadership

NuScale offers higher growth potential as the only approved SMR designer but faces years before revenue. Constellation Energy provides profitable operations, Microsoft/Meta contracts, and a growing dividend—making it the more prudent choice.

SMRMETAMSFT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

MVST Stock Plunges 34% After Disastrous Earnings; Law Firm Launches Fraud Investigation

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

MVSTMVSTW